normetanephrine has been researched along with Cardiovascular Diseases in 5 studies
Normetanephrine: A methylated metabolite of norepinephrine that is excreted in the urine and found in certain tissues. It is a marker for tumors.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms." | 1.72 | Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects. ( Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; Chamarthi, B; Chilton, R; Cincotta, AH; Cominos, N; DeFronzo, RA; Ezrokhi, M; Triplitt, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cincotta, AH | 1 |
| Cersosimo, E | 1 |
| Alatrach, M | 1 |
| Ezrokhi, M | 1 |
| Agyin, C | 1 |
| Adams, J | 1 |
| Chilton, R | 1 |
| Triplitt, C | 1 |
| Chamarthi, B | 1 |
| Cominos, N | 1 |
| DeFronzo, RA | 1 |
| Kohler, M | 1 |
| Pepperell, JC | 1 |
| Casadei, B | 1 |
| Craig, S | 1 |
| Crosthwaite, N | 1 |
| Stradling, JR | 1 |
| Davies, RJ | 1 |
| Enoz, M | 1 |
| Inancli, HM | 1 |
| Eisenhofer, G | 2 |
| Rundquist, B | 1 |
| Aneman, A | 1 |
| Friberg, P | 2 |
| Dakak, N | 1 |
| Kopin, IJ | 1 |
| Jacobs, MC | 1 |
| Lenders, JW | 2 |
| Pacak, K | 1 |
| Goldstein, DS | 1 |
| Murphy, DL | 1 |
| Tsigos, C | 1 |
| Quyyumi, AA | 1 |
| Brunner, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Association Between Enhanced Sympathetic Activity and Cardiometabolic Complications: a Cross-sectional Study on Predictive Power of 24-hour Urinary Metanephrines (SYMPACT)[NCT04495231] | 1,380 participants (Actual) | Observational | 2007-09-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for normetanephrine and Cardiovascular Diseases
| Article | Year |
|---|---|
CPAP and measures of cardiovascular risk in males with OSAS.
Topics: Adult; Aged; Baroreflex; Blood Pressure; Cardiovascular Diseases; Catecholamines; Continuous Positiv | 2008 |
4 other studies available for normetanephrine and Cardiovascular Diseases
| Article | Year |
|---|---|
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
Topics: Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycogen Synthase Kinase 3 beta; | 2022 |
CPAP and measures of cardiovascular risks in patients with OSAS.
Topics: Adult; Aged; Baroreflex; Blood Pressure; Cardiovascular Diseases; Catecholamines; Continuous Positiv | 2009 |
Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angina Pectoris; Cardiomyopathy, Dilated; Cardiovascular Disea | 1995 |
Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism?
Topics: Adrenal Glands; Adrenalectomy; Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Epinephrine; | 1995 |